MedImmune, Inc. is a biotechnology company that specializes in the development of therapies to prevent and treat infections and diseases caused by viruses, bacteria, and other pathogens. The company is headquartered in Gaithersburg, Maryland, and was founded in 1988. Uses MedImmune, Inc. has developed several therapies that are used to treat a range of medical conditions. One of the most notable is Synagis, a monoclonal antibody that is used to prevent respiratory syncytial virus (RSV) infections in infants and young children. This drug is administered via injection and is typically given monthly during RSV season. In addition to Synagis, MedImmune has also developed FluMist, a nasal spray flu vaccine. This vaccine is approved for use in healthy individuals aged 2 to 49 years and is designed to protect against the seasonal flu. Dosage The dosage of MedImmune's therapies varies depending on the indication and patient's age and weight. Synagis is typically given in a 15 mg/kg dose once monthly during RSV season and may be continued for up to five doses. FluMist is administered as a single spray per nostril in the recommended dose for the patient's age. Side Effects Like all medications, MedImmune's drugs can cause side effects. The most common side effects of Synagis include fever, cough, and wheezing. These side effects are generally mild and subside within a few days. FluMist can cause side effects such as nasal congestion, runny nose, headache, and sore throat. In rare cases, the vaccine can cause severe allergic reactions. Interactions It is important to inform your healthcare provider of any other medications you are taking before starting treatment with MedImmune's therapies. There are no known drug interactions with Synagis or FluMist. However, it is important to talk to your doctor about any potential interactions with other medications you are taking. Generic Neither of MedImmune's therapies has a generic equivalent at this time. However, as the patents for these drugs expire, generic versions may become available. It is important to talk to your healthcare provider about the most appropriate treatment for your medical condition. Demographic MedImmune's therapies are generally used in infants, young children, and healthy adults. Synagis is specifically approved for use in children who are at high risk for severe RSV infections. FluMist is approved for use in healthy individuals aged 2 to 49 years. In conclusion, MedImmune, Inc. is a biotechnology company that has developed several therapies to prevent and treat infections and diseases caused by viruses, bacteria, and other pathogens. These therapies include Synagis and FluMist, both of which are used to prevent respiratory infections. While these drugs can cause side effects, they are generally well-tolerated and are widely used in infants, young children, and healthy adults. It is important to talk to your healthcare provider about the most appropriate treatment for your specific medical condition.